Mito-Esculetin

Synonyms: Mito-Esc
Mito-Esculetin (Mito-Esc) 是一种具有口服活性的线粒体靶向 Esculetin (MS-B92735),可抑制 LPS 诱导的 STAT3 Tyr-705 磷酸化,部分逆转 LPS 介导的 SIRT3 耗竭,增强 AMPK-SIRT1 信号轴,抑制 PAI-1 活性,调控 miRNA、磷酸化 IRS 及磷酸化 AKT,并抑制氧化剂诱导的内皮功能障碍、Ang-II (MS-Y52939) 和高糖诱导的动脉粥样硬化斑块形成、Palmitate (MS-A29753) 诱导的胰岛素抵抗以及高糖介导的内皮细胞衰老与炎症反应,同时降低体重和游离脂肪酸 (NEFA) 水平,可用于急性冠状动脉综合征、2 型糖尿病及高血糖诱导的动脉粥样硬化相关研究。
产品编号: MS-I61644 CAS No.: 1993461-76-9 分子式: C35H36BrO4P 分子量: 631.54
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Mito-Esculetin (Mito-Esc) 是一种具有口服活性的线粒体靶向 Esculetin (MS-B92735),可抑制 LPS 诱导的 STAT3 Tyr-705 磷酸化,部分逆转 LPS 介导的 SIRT3 耗竭,增强 AMPK-SIRT1 信号轴,抑制 PAI-1 活性,调控 miRNA、磷酸化 IRS 及磷酸化 AKT,并抑制氧化剂诱导的内皮功能障碍、Ang-II (MS-Y52939) 和高糖诱导的动脉粥样硬化斑块形成、Palmitate (MS-A29753) 诱导的胰岛素抵抗以及高糖介导的内皮细胞衰老与炎症反应,同时降低体重和游离脂肪酸 (NEFA) 水平,可用于急性冠状动脉综合征、2 型糖尿病及高血糖诱导的动脉粥样硬化相关研究。

生物实验数据

生物活性 Mito-Esculetin (Mito-Esc) is an orally active mitochondria-targeted Esculetin (MS-B92735) that inhibits LPS-induced STAT3 Tyr-705 phosphorylation, partially reverses LPS-mediated SIRT3 depletion, enhances the AMPK-SIRT1 signaling axis, inhibits PAI-1 activity, regulates miRNA, phosphorylates IRS and phosphorylates AKT, and suppresses oxidant-induced endothelial dysfunction, Ang-II (MS-Y52939)- and high glucose-induced atherosclerotic plaque formation, Palmitate (MS-A29753)-induced insulin resistance, and high glucose-mediated endothelial cell senescence and inflammation, while reducing body weight and free fatty acid (NEFA) levels, and can be used for research on acute coronary syndrome, type 2 diabetes, and hyperglycemia-induced atherosclerosis.
体外研究
(In Vitro)

Mito-Esculetin (10 μM; 10 min) 在无细胞生化分析中可抑制重组 PAI-1 的活性。
Mito-Esculetin (2.5 μM; 2 h pretreatment) 可显著抑制脂多糖 (LPS) 诱导的主动脉内皮细胞 (HAECs) 中 PAI-1 活性及 mRNA 表达,其作用效力强于母体化合物 Esculetin (MS-B92735)。
Mito-Esculetin (2.5 μM; 2 h) 可抑制脂多糖 (LPS) 诱导的主动脉内皮细胞 (HAECs) 中 STAT3Tyr-705 的磷酸化。
Mito-Esc (1.25 μM; 6 h) 可抑制糖异生、恢复胰岛素信号通路、增强葡萄糖摄取,并在 Palmitate 诱导的胰岛素抵抗 HepG2 细胞中促进 GLUT4 转位。
Mito-Esc (1.25 μM; 1 h pre-incubation) 可抑制高糖诱导的单核细胞与 HAEC 的黏附。
Mito-Esc (1.25 μM; 1 h pre-incubation) 可减轻高糖诱导的衰老与氧化应激,恢复 HAEC 中的 AMPK-eNOS-SIRT1 信号通路,且该效应依赖于功能正常的 AMPK 与 SIRT1。

ELISA Assay

Cell Line: Human aortic endothelial cells (HAECs)
Concentration: 2.5 μM
Incubation Time: 2 h pretreatment, followed by 4 h LPS co-incubation
Result: Significantly inhibited LPS-induced PAI-1 activity in conditioned medium.
Significantly reduced LPS-induced PAI-1 transcript levels.
Exerted a more pronounced inhibitory effect than parent esculetin.

Western Blot Analysis

Cell Line: Human aortic endothelial cells (HAECs)
Concentration: 2.5 μM
Incubation Time: 2 h pretreatment, followed by 4 h LPS co-incubation
Result: Greatly inhibited LPS-induced increases in phospho-STAT3 (Tyr-705) protein levels.
体内研究
(In Vivo)

Mito-Esculetin (0.5 mg/kg;通过饮用水口服;每日;持续 2 个月) 可显著降低动脉粥样硬化 ApoE-/-小鼠中 Ang-II 诱导的 PAI-1 与 miR-19b 水平,同时恢复 miR-30c 水平。
Mito-Esculetin (0.312-1.25 mg/kg;口服;每日;30 天) 经口服给予 db/db 小鼠后,可通过减轻炎症、衰老和氧化应激,呈剂量依赖性地改善葡萄糖稳态、胰岛素抵抗、肝功能、脂肪组织健康以及高血糖诱导的动脉粥样硬化,其中 1.25 mg/kg 剂量的效果最佳。

Animal Model: ApoE-/- (2-month-old male, Angiotensin II-induced atherosclerosis)
Dosage: 0.5 mg/kg
Administration: p.o.; daily; 2 months
Result: Significantly inhibited Ang-II-induced plasma PAI-1 levels.
Repressed Ang-II-mediated elevation of aortic miR-19b levels.
Restored Ang-II-reduced aortic miR-30c levels.
Animal Model: db/db (4-month-old male/female; spontaneous hyperglycemia, insulin resistance, dyslipidemia)
Dosage: 0.312 mg/kg; 0.625 mg/kg; 1.25 mg/kg
Administration: p.o.; daily; 30 days
Result: Significantly reduced fasting and random blood glucose levels, and HbA1c levels relative to db/db controls.
Normalized serum insulin levels, and increased the quantitative insulin sensitivity check (QUICK) index dose-dependently.
Dose-dependently improved liver tissue morphology, reduced serum AST and ALT levels, decreased liver LDL-cholesterol and triglyceride levels, increased liver glycogen content, inhibited liver fructose-1,6-bisphosphatase (FBPase) activity, and reduced liver non-esterified free fatty acid (NEFA) levels relative to db/db controls.
Dose-dependently reduced adipocyte hypertrophy and lipid accumulation in adipose tissue relative to db/db controls, with greater reduction than simvastatin and pioglitazone.
Dose-dependently reduced aortic lesion area, collagen accumulation, and lipid accumulation relative to db/db controls; 0.625 and 1.25 mg/kg doses showed greater reduction than simvastatin and pioglitazone.
Significantly reduced serum LDL-cholesterol and triglyceride levels dose-dependently, while HDL levels were unchanged.
Significantly reduced mean arterial blood pressure.
Dose-dependently reduced aortic VCAM-1, ICAM-1, and MAC3 expression, normalized M1/M2 macrophage marker transcript levels in aorta, and reduced serum TNF-α, IL-1β, IL-6, IL-10, and MCP-1 levels relative to db/db controls; the 1.25 mg/kg dose showed greater reduction in TNF-α, IL-6, and MCP-1 than simvastatin and pioglitazone.
Dose-dependently reduced aortic transcript levels of senescence markers p16, p21, p27, and p53, restored aortic phospho-AMPK, phospho-eNOS, and SIRT1 protein levels, and increased serum GSH and nitrite/nitrate levels relative to db/db controls.

化学信息

分子量 631.54
分子式 C35H36BrO4P
CAS No. 1993461-76-9
别名 Mito-Esc

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础